Jefferies Initiates Coverage On MapLight Therapeutics with Buy Rating, Announces Price Target of $32
Benzinga Newsdesk 11 months ago
NewsPrice TargetInitiationAnalyst Ratings
Jefferies analyst Andrew Tsai initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Buy rating and announces Price Target of $32.
Jefferies analyst Andrew Tsai initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Buy rating and announces Price Target of $32.